The U.K. pharmaceutical company, GSK, is set to release its latest earnings report today. This comes at a difficult time for the pharmaceutical industry, as other major players have seen their stock prices decline after reporting their financial results. However, GSK’s American depositary receipt has managed to outperform many of its peers this year, making it one of the top performers in the group.
Analysts are anticipating GSK to report earnings of £0.46 per share for the quarter, with sales totaling £7.7 billion ($9.4 billion). This will be the first earnings report to include sales of GSK’s new respiratory syncytial virus vaccine, Arexvy, which launched earlier this year. The company has high hopes for this vaccine and expects it to become a huge success. Arexvy will be in direct competition with a similar shot developed by Pfizer.
Pfizer recently revealed that it generated $375 million from sales of its RSV vaccine, Abrysvo, during the third quarter. Interestingly, it was reported that two-thirds of RSV shots administered in the U.S. this season were GSK’s Arexvy.
In late October, GSK announced its plans to seek expanded regulatory approval for Arexvy for adults aged 50 to 59, based on data from a new Phase 3 study. Currently, the vaccine is approved for adults aged 60 and above.
Despite the challenging industry climate, GSK’s American depositary receipt is trading at 9.3 times earnings expected over the next 12 months, which is below its five-year average of 12.7 times earnings.
It will be interesting to see how investors react to GSK’s earnings report today and whether the company can continue its strong performance in the market.